What is the true target population for biologics in real-life COPD or asthma-COPD overlap patients?

ABSTRACT:

Introduction

Biologics provide significant benefits in asthma, reducing exacerbations and symptoms. Some biologics have shown promising results in small subgroups of patients with chronic obstructive pulmonary disease (COPD) and frequent exacerbations. Nevertheless, real-life data on the size of the COPD target population remain scarce.

Methods

We analysed the characteristics of COPD and coexisting asthma and COPD patients included in the prospective multicentre, French COhort of BRonchial obstruction and Asthma, between 2008 and 2023 and evaluated the number of patients who could correspond to the inclusion criteria of randomised controlled trials evaluating various biologics targeting interleukin 33 (IL-33) (-receptor), IL-5 (-receptor), IL-4Rα or TSLP, in routine clinical

SUBMITTER: Zysman M 

PROVIDER: S-EPMC11667443 | biostudies-literature | 2024 Dec

REPOSITORIES: biostudies-literature